Impaired liver glucose production in a murine model of steatosis and endotoxemia: Protection by inducible nitric oxide synthase

Antioxidants and Redox Signaling

Volumn 13, Issue 1, 2010, Pages 13-26

  Tirosh, Oren ^a   Artan, Avital ^a   Aharoni Simon, Michal ^a   Ramadori, Giuliano ^b   Madar, Zecharia ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; ETHIONINE; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; LIPOPOLYSACCHARIDE; NITRIC OXIDE DONOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; DIETARY INTAKE; ENDOTOXEMIA; FATTY LIVER; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HYPOGLYCEMIA; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; VITAMIN DEFICIENCY;

ANIMALS; CHOLINE DEFICIENCY; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; ETHIONINE; FATTY LIVER; GLUCOSE; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II;

MURINAE; MUS;

EID: 77953014474     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2789     Document Type: Article

References (41)

1. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, and Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11: 183-190, 2005.
2. Cheng PN, Leung YC, Lo WH, Tsui SM, and Lam KC. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Cancer Lett 224: 67-80, 2005.
3. Davies RA, Knight B, Tian YW, Yeoh GC, and Olynyk JK. Hepatic oval cell response to the choline-deficient, ethionine supplemented model of murine liver injury is attenuated by the administration of a cyclo-oxygenase 2 inhibitor. Carci-nogenesis 27: 1607-1616, 2006.
4. Denmark LN. The investigation of beta-hydroxybutyrate as a marker for sudden death due to hypoglycemia in alcoholics. Forens Sci Int 62: 225-232, 1993.
5. Fan JG and Qiao L. Commonly used animal models of nonalcoholic steatohepatitis. Hepatobiliary Pancreat Dis Int 8: 233-240, 2009.
6. Feingold KR, Moser A, Patsek SM, Shigenaga JK, and Grun-feld C. Infection decreases fatty acid oxidation and nuclear hormone receptors in the diaphragm. J Lipid Res 50: 2055-2063, 2009.
7. Feingold KR, Wang Y, Moser A, Shigenaga JK, and Grunfeld C. LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney. J Lipid Res 49: 2179-2187, 2008.
8. Folch J, Lees M, and Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509, 1957.
9. Fujimoto M, Shimizu N, Kunii K, Martyn JA, Ueki K, and Kaneki M. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes 54: 1340-1348, 2005.
10. Jacobs RL, Lingrell S, Zhao Y, Francis GA, and Vance DE. Hepatic CTP:phosphocholine cytidylyltransferase-alpha is a critical predictor of plasma high density lipoprotein and very low density lipoprotein. J Biol Chem 283: 2147-2155, 2008.
11. Kagansky N, Levy S, Rimon E, Cojocaru L, Fridman A, Ozer Z, and Knobler H. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 163: 1825-1829, 2003.
12. Kanner J, Harel S, and Granit R. Nitric oxide as an antioxi-dant. Arch Biochem Biophys 289: 130-136, 1991.
13. Kanner J, Harel S, and Granit R. Nitric oxide, an inhibitor of lipid oxidation by lipoxygenase, cyclooxygenase and hemoglobin. Lipids 27: 46-49, 1992.
14. Kim MS, Shigenaga JK, Moser AH, Feingold KR, and Grunfeld C. Suppression of estrogen-related receptor alpha and medium-chain acyl-coenzyme A dehydrogenase in the acute-phase response. J Lipid Res 46: 2282-2288, 2005.
15. Koskinas J, Gomatos IP, Tiniakos DG, Memos N, Boutsikou M, Garatzioti A, Archimandritis A, and Betrosian A. Liver histology in ICU patients dying from sepsis: a clinico-pathological study. World J Gastroenterol 14: 1389-1393, 2008.
16. Krinsley JS. The severity of sepsis: yet another factor influencing glycemic control. Crit Care 12: 194, 2008.
17. Larter CZ and Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23: 1635-1648, 2008.
18. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, and Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 47: 142-156, 2007.
19. Liu J and Waalkes MP. Nitric oxide and chemically induced hepatotoxicity: beneficial effects of the liver-selective nitric oxide donor, V-PYRRO=NO. Toxicology 208: 289-297, 2005.
20. Lo YC, Wang CC, Shen KP, Wu BN, Yu KL, and Chen IJ. Urgosedin inhibits hypotension, hypoglycemia, and pro-inflammatory mediators induced by lipopolysaccharide. J Cardiovasc Pharmacol 44: 363-371, 2004.
21. Maitra SR, Gestring ML, El-Maghrabi MR, Lang CH, and Henry MC. Endotoxin-induced alterations in hepatic glucose-6-phosphatase activity and gene expression. Mol Cell Biochem 196: 79-83, 1999.
22. Mantena SK, King AL, Andringa KK, Eccleston HB, and Bailey SM. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol, and obesity-induced fatty liver diseases. Free Radic Biol Med 44: 1259-1272, 2008.
23. Nisoli E and Carruba MO. Nitric oxide and mitochondrial biogenesis. J Cell Sci 119: 2855-2862, 2006.
24. Nisoli E, Clementi E, Carruba MO, and Moncada S. Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res 100: 795-806, 2007.
25. Oguri S, Motegi K, Iwakura Y, and Endo Y. Primary role of interleukin-1 alpha and interleukin-1 beta in lipopolysac-charide-induced hypoglycemia in mice. Clin Diagn Lab Immunol 9: 1307-1312, 2002.
26. Puigserver P and Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 24: 78-90, 2003.
27. Raddatz D and Ramadori G. Carbohydrate metabolism and the liver: actual aspects from physiology and disease. Z Gastroenterol 45: 51-62, 2007.
28. Rai RM, Lee FY, Rosen A, Yang SQ, Lin HZ, Koteish A, Liew FY, Zaragoza C, Lowenstein C, and Diehl AM. Impaired liver regeneration in inducible nitric oxide synthase deficient mice. Proc Natl Acad Sci USA 95: 13829-13834, 1998.
29. Randall B. Fatty liver and sudden death: a review. Hum Pathol 11: 147-153, 1980.
30. Roth E, Steininger R, Winkler S, Langle F, Grunberger T, Fugger R, and Muhlbacher F. L-Arginine deficiency after liver transplantation as an effect of arginase efflux from the graft: influence on nitric oxide metabolism. Transplantation 57: 665-669, 1994.
31. Ruetten H and Thiemermann C. Effect of calpain inhibitor I, an inhibitor of the proteolysis of I kappa B, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. Br J Pharmacol 121: 695-704, 1997. (Pubitemid 27260772)
32. Shimano H. SREBP-1c and TFE3, energy transcription factors that regulate hepatic insulin signaling. J Mol Med 85: 437-444, 2007.
33. Sugita H, Kaneki M, Tokunaga E, Sugita M, Koike C, Yasuhara S, Tompkins RG, and Martyn JA. Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance. Am J Physiol Endocrinol Metab 282: E386-E394, 2002.
34. Thompson BT. Glucose control in sepsis. Clin Chest Med 29: 713-720, x, 2008.
35. van der Crabben SN, Blumer RM, Stegenga ME, Ackermans MT, Endert E, Tanck MW, Serlie MJ, van der Poll T, and Sauerwein HP. Early endotoxemia increases peripheral and hepatic insulin sensitivity in healthy humans. J Clin En-docrinol Metab 94: 463-468, 2009.
36. Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, and Martinez-Chantar ML. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol 41: 969-976, 2009.
37. Volk J, Gorelik S, Granit R, Kohen R, and Kanner J. The dual function of nitrite under stomach conditions is modulated by reducing compounds. Free Radic Biol Med 47: 496-502, 2009.
38. Weickert MO and Pfeiffer AF. Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia 49: 1732-1741, 2006.
39. Yang S, Lin H, and Diehl AM. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol 281: G382-G392, 2001.
40. Yang SQ, Lin HZ, Lane MD, Clemens M, and Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 94: 2557-2562, 1997.
41. Yuzuriha T, Okudaira M, Tominaga I, Hori S, Suzuki H, Matsuo Y, Shoji M, Yokoyama A, Takagi S, and Hayashida M. Alcohol-related sudden death with hepatic fatty metamorphosis: a comprehensive clinicopathological inquiry into its pathogenesis. Alcohol Alcohol 32: 745-752, 1997.